Also trades as: 0R1F.L (LSE) · $vol 1M · 0R1F.IL (IOB) · $vol 1M · BRM.DE (XETRA) · $vol 0M · BMY.SW (SIX) · $vol 0M
BMY NYSE
Bristol-Myers Squibb Company
1W: +4.7%
1M: -1.0%
3M: -2.1%
YTD: +18.9%
1Y: +46.8%
3Y: +25.6%
5Y: +33.1%
$61.55
-0.06 (-0.10%)
After Hours: $61.91 (+0.37, +0.59%)
Weekly Expected Move ±5.2%
$55
$58
$61
$65
$68
Credit Risk of going bust: lower than 72% of companies Debt: 25.5% of company value Bonds: $498.7M held by 336 funds, 76 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.26 (down 98%), Bristol-Myers Squibb Company would be worth roughly what it owes.
Total debt $43.12B against a stock market value of $125.85B.
Distance to default 7.92 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $22.07B (short-term plus half of long-term), stock volatility 28.2%; Altman Z 2.67. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.26 (down 98%), Bristol-Myers Squibb Company would be worth roughly what it owes.
Total debt $43.12B against a stock market value of $125.85B.
Distance to default 7.92 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $22.07B (short-term plus half of long-term), stock volatility 28.2%; Altman Z 2.67. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$49B
Revenue
+3.1% YoY
$9B
Net Income
+83.8% YoY
$11B
Free Cash Flow
-21.5% YoY
71.3%
Gross Margin
31.0%
Op. Margin
25.6%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE46.7%
ROA10.2%
ROIC17.8%
Valuation
P/E13.5
P/B5.6
EV/EBITDA9.2
Leverage
Debt/Equity1.93
Current Ratio1.53
Interest Cov.9.7x
Quality Scores
Piotroski F8/9
Altman Z2.58
Beneish M-2.98